Enhancing Biomarker-Driven Care and Disability Detection in Multiple Sclerosis: Clinical and Pharmacy Practice Strategies
EP. 1: Understanding the Multiple Sclerosis Disease Continuum and the Consequences of Untreated Progression
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Explore innovative strategies for identifying and managing multiple sclerosis through expert insights on biomarker-driven care and clinical practices.
EP. 2: Pharmacist Best Practices in Early Multiple Sclerosis Detection and Disability Identification
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Discover the significance of PIRA in multiple sclerosis (MS) and how pharmacists enhance early detection and patient care in MS management.
EP. 3: Biomarkers, Evolving Subtypes, and Redefining Disease Classification in Multiple Sclerosis
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Learn how MRI, OCT, and CSF markers refine MS diagnosis and monitoring, and why “active” disease matters beyond relapses.
EP. 4: Neuroinflammation and Disability Progression: Evolving Insights in Multiple Sclerosis
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Learn how diffuse neuroinflammation drives progressive MS, how MRI finds paramagnetic rim lesions, and which cognitive and physical tests track disability over time.
EP. 5: Bridging Diagnostic Gaps and Advancing Endpoints to Address Smoldering Progression in Multiple Sclerosis
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Learn how hidden neuroinflammation drives MS progression, why MRI may miss it, and how rim lesions and testing track disability.
EP. 6: Shifting Focus to Long-Term Disability and Novel Therapeutic Pathways in Multiple Sclerosis
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS MS experts say MRI and current trial endpoints miss “smoldering” progression; emerging biomarkers, 7T imaging, PROs, and CNS-penetrant therapies aim to close gaps.
EP. 7: Advancing BTK Inhibitors in MS: Insights from Clinical Trials and Early Safety Data
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Why MS relapses aren’t the whole story: experts explain PIRA, the push for remyelination, and how BTK inhibitors may reach the CNS.
EP. 8: Fenebrutinib and the Future Role of BTK Inhibitors in MS Treatment
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Finibrutinib’s phase 3 MS results hint at new hope for relapsing and progressive disease, as experts weigh safety and monitoring.
EP. 9: Emerging Mechanisms and the Future of Multiple Sclerosis Treatment
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Experts explore emerging multiple sclerosis treatments, from brain-protective PDE4 inhibitors and remyelination to CAR T, stem cell transplant, and easier anti-CD20 options.
EP. 10: The Expanding Role of Pharmacists in Patient Education and REMS Management in Multiple Sclerosis
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Explore emerging multiple sclerosis treatments, from brain-protective targets and remyelination to CAR-T, stem cell transplants, and more accessible anti-CD20 options.
EP. 11: Optimizing MS Therapy Management: REMS and Routes of Administration
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Explore who drives REMS success—from FDA and manufacturers to pharmacists and patients—and how MS therapy routes shape safety, adherence, and workflow.
EP. 12: Redefining Treatment Success and Monitoring in nrSPMS
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Experts weigh EDSS vs patient-reported symptoms in SPMS, urging composite endpoints, MRI insights, and smarter coding to improve therapy access.
EP. 13: Payer Considerations for Formulary Placement and Final Panelist Thoughts in MS and nrSPMS
ByJacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,Kiranpal Singh Sangha, PharmD,Ryan Fuller, PharmD,Aimee M. Banks, PharmD, BCPS, MSCS,Millad Sobhanian, PharmD, BCPS Experts debate tracking MS progression beyond EDSS, blending patient-reported symptoms, MRI metrics, and new ICD-10 coding for access.
